Program
Oxaliplatin
Also written as “oxaliplatin”, “Oxaliplatin (SR96669)” and “oxaliplatin (OXA), levofolinate calcium (l-LV), 5-FU, panitumumab”.
Its studies are mostly in Colorectal Neoplasms · Stomach Neoplasms · Pancreatic Neoplasms · Rectal Neoplasms · Carcinoma, Hepatocellular, led by 9 companies.
Drug pageOxaliplatin: every studyMany companies study it; this page follows only the 66 they lead. All 854 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Sanofiits history only | 360 open or running | phase 4since Aug 10, 2005 | Jan 6, 2001 | none ahead |
| Hoffmann-La Roche | 201 open or running | phase 4since Dec 18, 2007 | Sep 15, 2003 | Mar 22, 2027phase 1 · NCT06624085 |
| Prologue Research Internationalits history only | 30 open or running | phase 3since Jun 5, 2003 | May 6, 2001 | none ahead |
| Pfizerits history only | 21 open or running | phase 3since Oct 5, 2020 | Nov 6, 2007 | none ahead |
| Criteriumits history only | 10 open or running | phase 2since Sep 24, 2019 | Sep 24, 2019 | none ahead |
| GlaxoSmithKlineits history only | 10 open or running | phase 1since Sep 27, 2007 | Sep 27, 2007 | none ahead |
| Nang Kuang Pharmaceuticalits history only | 10 open or running | phase 2since Mar 28, 2011 | Mar 28, 2011 | none ahead |
| NovoCureits history only | 10 open or running | no phasesince Feb 20, 2020 | Feb 20, 2020 | none ahead |
| Sirtex Medicalits history only | 10 open or running | phase 3since Aug 13, 2008 | Aug 13, 2008 | none ahead |
Also a collaborator on its studies: Exelixis, Novartis, Clovis Oncology, Johnson & Johnson, Ono Pharmaceutical, Merck KGaA, Darmstadt, Germany, Eli Lilly, Parexel, Halozyme Therapeutics, BioLineRx, AbbVie, Zai Lab, Amgen, Bristol-Myers Squibb, Regeneron Pharmaceuticals and Yakult Honsha.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Hoffmann-La Roche only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 6 studies since Sep 15, 2003.
- Dec 18, 2007Phase 4 study in Colorectal NeoplasmsNCT00577031 · 205 enrolled · Italy
- Feb 18, 2008Phase 3 study in Colorectal NeoplasmsNCT00623805 · 123 enrolled · Turkey
- Mar 19, 2008Phase 2 study in Colorectal NeoplasmsNCT00642603 · 41 enrolled · United States
- Jun 17, 2008Phase 2 study in Colorectal NeoplasmsNCT00700570 · 45 enrolled · Taiwan
- Feb 26, 2010Phase 2 study in Colorectal NeoplasmsNCT01077739 · 75 enrolled · Belgium
- May 25, 2010Phase 2 study in Stomach NeoplasmsNCT01130337 · 36 enrolled · Spain
- Jun 1, 2010Phase 2 study in Colorectal NeoplasmsNCT01135498 · 90 enrolled · Spain
- Jul 7, 2010Phase 2 study in Colorectal NeoplasmsNCT01159171 · 50 enrolled · Italy
- Dec 10, 2012Phase 2 study in Stomach NeoplasmsNCT01748773 · 34 enrolled · Turkey
- May 15, 2014Phase 2 study in Colorectal NeoplasmsNCT02141295 · 197 enrolled · United States, Australia, Austria and more
- Sep 24, 2015Phase 3 study in Stomach NeoplasmsNCT02560974 · 1,035 enrolled · China, Korea, Republic of, Taiwan
- Feb 25, 2016Phase 2 study in Rectal NeoplasmsNCT02694718 · 60 enrolled · Switzerland
- Sep 11, 2017Phase 2 study in Esophageal NeoplasmsNCT03281369 · 219 enrolled · United States, Australia, Israel and more
- Oct 1, 2024Phase 1 study in LymphomaNCT06624085 · 50 enrolled · United States, Puerto Rico
Ahead
- Mar 22, 2027Primary completion: phase 1 study in LymphomaNCT06624085
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 20 Hoffmann-La Roche leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06624085Lymphoma · United States, Puerto Rico | 1 | Active, not recruiting | Mar 22, 2027 | 50 |
| NCT03281369Esophageal Neoplasms · United States, Australia, Israel and more | 2 | Terminated | Oct 9, 2025 | 219 |
| NCT02694718Rectal Neoplasms · Switzerland | 2 | Completed | Aug 2006 | 60 |
| NCT02560974Stomach Neoplasms · China, Korea, Republic of, Taiwan | 3 | Completed | Nov 2012 | 1,035 |
| NCT02141295Colorectal Neoplasms · United States, Australia, Austria and more | 2 | Terminated | Jul 29, 2016 | 197 |
| NCT01748773Stomach Neoplasms · Turkey | 2 | Completed | Aug 21, 2015 | 34 |
| NCT01159171Colorectal Neoplasms · Italy | 2 | Completed | Jul 2010 | 50 |
| NCT01135498Colorectal Neoplasms · Spain | 2 | Completed | Apr 2010 | 90 |
| NCT01130337Stomach Neoplasms · Spain | 2 | Completed | Jun 2014 | 36 |
| NCT01077739Colorectal Neoplasms · Belgium | 2 | Completed | Jan 2012 | 75 |
| NCT00700570Colorectal Neoplasms · Taiwan | 2 | Completed | Nov 2011 | 45 |
| NCT00642603Colorectal Neoplasms · United States | 2 | Terminated | Mar 2009 | 41 |
| NCT00623805Colorectal Neoplasms · Turkey | 3 | Completed | May 2012 | 123 |
| NCT00577031Colorectal Neoplasms · Italy | 4 | Completed | Aug 2011 | 205 |
| NCT00439426Nasopharyngeal Neoplasms · Morocco | 2 | Completed | Sep 2009 | 25 |
| NCT00436241Stomach Neoplasms · Taiwan | 2 | Completed | Nov 2010 | 45 |
| NCT00353262Colorectal Neoplasms · Canada | 1 | Completed | Sep 2006 | 36 |
| NCT00345761Colorectal Neoplasms · Japan | 2 | Completed | Oct 2008 | 64 |
| NCT00069121Colorectal Neoplasms · United States, Australia, Belgium and more | 3 | Completed | Apr 21, 2011 | 1,886 |
| NCT00069095Colorectal Neoplasms · United States, Australia, Austria and more | 3 | Completed | Jan 2006 | 2,035 |
How it is read
Names in the registry
- “Oxaliplatin”, 51 entries
- “oxaliplatin”, 20 entries
- “Oxaliplatin (SR96669)”, 3 entries
- “oxaliplatin (OXA), levofolinate calcium (l-LV), 5-FU, panitumumab”, 3 entries
- “OXALIPLATIN”, 3 entries
Conditions, from the studies’ own filings
- Colorectal Neoplasms, 35 studies
- Stomach Neoplasms, 16 studies
- Pancreatic Neoplasms, 7 studies
- Rectal Neoplasms, 6 studies
- Carcinoma, Hepatocellular, 4 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.